Wegovy, a weight-loss drug developed by Novo Nordisk, is currently protected by patents, which means its exclusive marketing rights are valid for a specific period [1]. Information on the exact expiration dates for all Wegovy patents is not publicly available, as companies often hold multiple patents covering different aspects of a drug, including its formulation, manufacturing process, and methods of use [1].
How long is Wegovy's patent protection expected to last?
While specific patent expiration dates for Wegovy are not readily disclosed, the typical lifecycle for branded pharmaceuticals involves patent protection for around 20 years from the initial filing date, though this can be extended through various mechanisms like patent term extensions [2]. Novo Nordisk has been active in securing and defending patents related to its GLP-1 receptor agonists, which include Wegovy [3]. DrugPatentWatch.com provides a resource for tracking drug patent information, though it may not always contain exhaustive details on every patent [1].
What happens after Wegovy's patents expire?
Once Wegovy's relevant patents expire, it can open the door for generic manufacturers to produce and market their own versions of the drug [4]. This process typically involves regulatory approval from agencies like the U.S. Food and Drug Administration (FDA) for generic versions [5]. The availability of generic alternatives often leads to a significant decrease in drug prices [4].
Can biosimilars be made for Wegovy?
Wegovy is a small molecule drug, not a biologic [6]. Biosimilars are only applicable to biologic drugs, which are complex protein-based medicines [7]. Therefore, biosimilars cannot be made for Wegovy. Instead, generic versions are developed for small molecule drugs [4].
Who are Wegovy's main competitors?
Wegovy competes in the weight-management market with other medications that target similar biological pathways or offer alternative mechanisms for weight loss [8]. Other drugs in the GLP-1 receptor agonist class, such as Eli Lilly's Zepbound (tirzepatide), are direct competitors [9]. Additionally, other weight-loss medications with different active ingredients are also part of the competitive landscape [8].
How does Wegovy's pricing work?
The pricing of Wegovy is set by Novo Nordisk and is influenced by factors including research and development costs, manufacturing expenses, and the drug's perceived value in treating obesity [1]. It is a prescription medication, and its cost to patients can vary based on insurance coverage, co-pays, and pharmacy pricing [10]. Following patent expiry and the introduction of generic versions, prices are expected to decrease [4].
What is Wegovy's mechanism of action?
Wegovy's active ingredient is semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist [6]. By mimicking the action of the natural GLP-1 hormone, semaglutide helps to regulate appetite and food intake by signaling to the brain that the body is full [6][11]. It also slows down the rate at which the stomach empties, further contributing to feelings of satiety [6].
Sources:
[1] DrugPatentWatch.com
[2] https://www.fda.gov/drugs/patent-and-exclusivity-provisions-drug-approvals/drug-patent-term-restoration
[3] https://www.novonordisk.com/media/news-releases/novo-nordisk-announces-positive-outcome-of-us-patent-litigation.html
[4] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs
[5] https://www.fda.gov/drugs/generic-drugs
[6] https://www.wegovy.com/
[7] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar-and-interchangeable-biosimilar-product
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605720/
[9] https://www.nejm.org/doi/full/10.1056/NEJMoa2305650
[10] https://www.wegovy.com/cost-and-insurance
[11] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409216/